Expert Opinion on Investigational Drugs 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30:1-6. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side eff...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2277389. Online ahead of print.ABSTRACTINTRODUCTION: Chronic hepatitis B infection is a major global health issue associated with significant liver-related morbidity and mortality. While existing treatments can suppress the virus effectively, they are incapable of inducing functional cure, as defined by hepatitis B surface antigen (HBsAg) seroclearance. Currently, numerous novel compounds are being developed, including bepirovirsen which is an antisense oligonucleotide (ASO).AREAS COVERED: This review summarizes the mechanism of action, pharmacokinetics, c...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lung-Yi Mak Rex Wan-Hin Hui James Fung Wai-Kay Seto Man-Fung Yuen Source Type: research
Investigational drugs inhibiting complement for the treatment of geographic atrophy
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2276759. Online ahead of print.ABSTRACTINTRODUCTION: Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA.AREAS COVERED: This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Specific...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lorenzo Ferro Desideri Dmitri Artemiev Enrico Bernardi Karin Paschon Souska Zandi Martin Zinkernagel Rodrigo Anguita Source Type: research
Hepatic encephalopathy: investigational drugs in preclinical and early phase development
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2277386. Online ahead of print.ABSTRACTINTRODUCTION: Hepatic encephalopathy (HE) is a neuropsychiatric syndrome, in patients with liver disease, which affects life quality and span. Current treatments are lactulose or rifaximin, acting on gut microbiota. Treatments aiming ammonia levels reduction have been tested with little success.AREAS COVERED: Pre-clinical research shows that the process inducing HE involves sequentially: liver failure, altered microbiome, hyperammonemia, peripheral inflammation, changes in immunophenotype and extracellular vesicles an...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Tiziano Balzano Marta Llansola Yaiza M Arenas Paula Izquierdo-Altarejos Vicente Felipo Source Type: research
Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2277389. Online ahead of print.ABSTRACTINTRODUCTION: Chronic hepatitis B infection is a major global health issue associated with significant liver-related morbidity and mortality. While existing treatments can suppress the virus effectively, they are incapable of inducing functional cure, as defined by hepatitis B surface antigen (HBsAg) seroclearance. Currently, numerous novel compounds are being developed, including bepirovirsen which is an antisense oligonucleotide (ASO).AREAS COVERED: This review summarizes the mechanism of action, pharmacokinetics, c...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lung-Yi Mak Rex Wan-Hin Hui James Fung Wai-Kay Seto Man-Fung Yuen Source Type: research
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
Expert Opin Investig Drugs. 2023 Oct 28. doi: 10.1080/13543784.2023.2277385. Online ahead of print.ABSTRACTINTRODUCTION: Chronic urticaria (CU), including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is a prevalent, enduring, mast-cell driven condition that presents challenges in its management. There is a clear need for additional approved treatment options beyond H1 receptor antagonists and the anti-IgE monoclonal antibody (mAb), omalizumab. One of the latest therapeutic strategies targets KIT, which is considered the primary master regulator for mast cell-related disorders.AREASCOVERED: T...
Source: Expert Opinion on Investigational Drugs - October 28, 2023 Category: Drugs & Pharmacology Authors: Bettina Wedi Source Type: research
Experimental drugs for Friedrich's ataxia: progress and setbacks in clinical trials
Expert Opin Investig Drugs. 2023 Oct 27. doi: 10.1080/13543784.2023.2276758. Online ahead of print.NO ABSTRACTPMID:37886821 | DOI:10.1080/13543784.2023.2276758 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - October 27, 2023 Category: Drugs & Pharmacology Authors: Sylvia Boesch Elisabetta Indelicato Source Type: research
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension
Expert Opin Investig Drugs. 2023 Oct 26. doi: 10.1080/13543784.2023.2274439. Online ahead of print.ABSTRACTINTRODUCTION: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease. Approved treatment options currently primarily target abnormal cell signaling pathways involved in vasoconstriction and proliferation, such as those mediated by prostacyclin, cyclic guanosine monophosphate, and endothelin.AREAS COVERED: Recent advancements have led to new applications and modes of delivery of currently approved PAH medications. At the same time, novel drugs targeting specific molecular pathways involved ...
Source: Expert Opinion on Investigational Drugs - October 26, 2023 Category: Drugs & Pharmacology Authors: Roger Auth James R Klinger Source Type: research
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension
This article encapsulates the current state of knowledge regarding Baxdrostat, encompassing its uses, ongoing clinical trials, and potential future clinical applications.EXPERT OPINION: Future research endeavors will play a pivotal role in unveiling the effectiveness and safety profile of this novel medication. Thus, positioning baxdrostat as a valuable addition to the armamentarium of antihypertensive agents, especially for patients with complex, multifactorial hypertensive conditions.PMID:37883217 | DOI:10.1080/13543784.2023.2276755 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - October 26, 2023 Category: Drugs & Pharmacology Authors: Ayoola Awosika Yoonje Cho Ujjal Bose Adekunle E Omole Uzochukwu Adabanya Source Type: research
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension
Expert Opin Investig Drugs. 2023 Oct 26. doi: 10.1080/13543784.2023.2274439. Online ahead of print.ABSTRACTINTRODUCTION: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease. Approved treatment options currently primarily target abnormal cell signaling pathways involved in vasoconstriction and proliferation, such as those mediated by prostacyclin, cyclic guanosine monophosphate, and endothelin.AREAS COVERED: Recent advancements have led to new applications and modes of delivery of currently approved PAH medications. At the same time, novel drugs targeting specific molecular pathways involved ...
Source: Expert Opinion on Investigational Drugs - October 26, 2023 Category: Drugs & Pharmacology Authors: Roger Auth James R Klinger Source Type: research
Assessing potential of psilocybin for depressive disorders
Expert Opin Investig Drugs. 2023 Oct 23. doi: 10.1080/13543784.2023.2273493. Online ahead of print.ABSTRACTINTRODUCTION: There has been increasing interest in the role psilocybin may play inthe treatment of depressive disorders. Several clinical trials haveshown psilocybin to have efficacy in reducing symptoms of depression.AREASCOVERED: We discuss the current understanding of psilocybin'stherapeutic mechanism of action and review existing clinical datainvestigating psilocybin as a novel therapeutic agent for thetreatment of depression.EXPERTOPINION: There is still much unknown regarding the risks ofpsilocybin treatment. W...
Source: Expert Opinion on Investigational Drugs - October 23, 2023 Category: Drugs & Pharmacology Authors: Zofia Kozak Matthew W Johnson Scott T Aaronson Source Type: research
A phase I, randomized, Double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects
CONCLUSION: Thisstudy demonstrated PK bioequivalence between SB16, EU-DEN, and US-DEN inhealthy male subjects.TRIALREGISTRATION: CT.gov identifier:NCT04621318.PMID:37870163 | DOI:10.1080/13543784.2023.2273510 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - October 23, 2023 Category: Drugs & Pharmacology Authors: Hyuna Lee Sujung Kim Hyoryeong Seo Soyeon Kim Source Type: research
